ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  Related Studies  
BVAIT: B-Vitamin Atherosclerosis Intervention Trial

This study has been completed.
Information provided by National Institute on Aging (NIA)

This Tabular View shows the required WHO registration data elements as marked by

Descriptive Information Fields
Brief Title  BVAIT: B-Vitamin Atherosclerosis Intervention Trial
Official Title  B-Vitamin Atherosclerosis Intervention Trial (BVAIT)
Brief Summary

The purpose of this study is to examine whether vitamin B supplementation will reduce the progression of early atherosclerosis in individuals over 40 years old and without clinical evidence of cardiovascular disease (CVD).

Detailed Description

The primary hypothesis to be tested is that daily vitamin B supplementation reduces progression of early atherosclerosis. Ultrasonography will be used to measure the rate of change in the thickness of the carotid artery and CT will be used to measure coronary and aortic calcium. The beneficial effects of vitamin B supplementation are expected to occur with or without a change in LDL-C levels.

A total of 506 men and women will be randomized to receive either 1) vitamin B supplementation consisting of folic acid 5mg, vitamin B12 0.4mg, and vitamin B6 50mg, or 2) a matching placebo. Participants will receive ultrasonography at baseline and every 6 months for 2.5 to 4.5 years, and CT scan at baseline and end of study (2.5 to 4.5 years).

Study Phase Phase II, Phase III
Study Type  Interventional
Study Design  Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Primary Outcome Measure  rate of change of distal common carotid artery (CCA) far wall intima-media thickness (IMT)
Secondary Outcome Measure  change in coronary and abdominal aortic calcification
neurocognitive change
Condition  Atherosclerosis
Intervention  Drug: folic acid
Drug: vitamin B12
Drug: vitamin B6
MEDLINE PMIDs
Links
Recruitment Information Fields
Recruitment Status  Completed
Enrollment  506
Start Date  November 2000
Completion Date February 2007
Eligibility Criteria 

Inclusion Criteria:

  • Male or female (postmenopausal)
  • 40 years or older
  • Fasting plasma homocysteine 8.5 micromoles per liter (µmol/L) or greater

Exclusion Criteria:

  • Any clinical signs or symptoms of cardiovascular disease (CVD)
  • Diabetes mellitus or fasting serum glucose 140 mg/dL or greater
  • Triglyceride (TG) levels 500mg/dL or greater
  • Serum creatinine greater than 1.6 mg/dL
  • Uncontrolled hypertension (systolic blood pressure 160 mmHg or greater and/or diastolic blood pressure 100 mmHg or greater)
  • Thyroid disease (untreated)
  • Life threatening disease with prognosis less than 5 years
  • Alcohol intake greater than 5 drinks per day (1 drink = 1 1/2 oz distilled spirits, 4 oz wine, or 12 oz beer) or substance abuse (intravenous drug use, cocaine use)
Gender Both
Ages 40 Years and older
Accepts Healthy Volunteers Yes
Contacts ††
Location Countries  United States
Administrative Information Fields
NCT ID  NCT00114400
Organization ID AG0024
Secondary IDs †† R01AG017160
Study Sponsor  National Institute on Aging (NIA)
Collaborators †† Leiner Health Products
Investigators 
Principal Investigator:     Howard N. Hodis, MD     University of Southern California, Atherosclerosis Research Unit, Division of Cardiovascular Medicine, Department of Medicine    
Information Provided By National Institute on Aging (NIA)
Verification Date February 2007
First Received Date  June 14, 2005
Last Updated Date February 15, 2007

 †    Required WHO trial registration data element.
††   WHO trial registration data element that is required only if it exists.




Links to all studies - primarily for crawlers